Press "Enter" to skip to content

Big Pharma firms aim to make 200 MILLION flu vaccine doses amid pandemic

Healthcare providers, including CVS, are kicking off flu vaccinations early, ordering extra shots and aiming to add tests that check for both the annual flu and COVID-19, pharmacy executives and experts told Reuters.

Flu vaccination for the fall has taken on increased urgency because of the potential for serious complications if patients contract both viruses at once.

Vaccine makers will provide nearly 200 million flu vaccines to the United States this year, potentially 20 percent more than typical, said LJ Tan, chief strategy officer for the Immunization Action Coalition, a nonprofit that promotes vaccination.

Manufacturers who have promised to contribute to the ramped up vaccine production include AstraZeneca, GlaxoSmithKline and Sanofi – all of which are also racing to make effective coronavirus vaccines as well. 

CVS expects to more than double the number of flu shots it provides to around 18 million people and Walgreens Boots Alliance Inc is stockpiling extra vaccines, the companies told Reuters.

Failure to inoculate for the flu could also strain the United States COVID-19 testing capacity, which is still below the 6-10 million daily tests needed, Reuters has reported.

‘If we can eliminate the dynamic of people getting symptoms and their first reaction is `is this the seasonal flu or is this COVID,´ it can take demand off of COVID-19 testing,’ CVS Chief Executive Larry Merlo told Reuters.

Merlo added that CVS is working to obtain tests that screen for both viruses simultaneously. 

US regulators approved a joint COVID-19 and flu test in July.

The same people who are most vulnerable to risks from COVID-19, such as the elderly and those with respiratory conditions, are also at greatest risk for the flu, Tan added.

The U.S. healthcare system is already expected to be strained in the fall by a resurgence in COVID-19. The Institute for Health Metrics and Evaluation is anticipating an uptick in COVID-19 cases in the coming months, resulting in around 300,000 total deaths by December, up from the current figure of roughly 160,000, and a nearly 75% increase in hospitalizations.

There is evidence that social distancing measures for COVID-19 reduce the transmission rate of the flu as well, according to the U.S. Centers for Disease Control and Prevention, meaning that continued measures in the U.S. could potentially slow flu transmission this season.

However, efforts to inoculate patients for the flu could be complicated by the need to safeguard patients and healthcare workers from COVID-19.

‘If a patient has a fever or other symptoms associated with illness, they will be referred to their healthcare provider and immunizations will be deferred,’ a Walgreens spokeswoman told Reuters.

CVS plans to begin inoculating patients earlier than usual – possibly by the end of this month – to get a jump start on preparing for this year’s flu season, which usually starts around October.

However, studies show there is a risk that getting inoculated against the flu too early can leave a patient vulnerable to contracting the virus later on in winter, if the shot wears off.

Other physicians are also starting this month, though it will still take months to fully distribute all the needed inoculations, Tan said.

The flu vaccine ‘comes out over time so you want to make sure people continue to seek flu vaccines’ through Thanksgiving and beyond, Tan said. (Reporting by Carl O’Donnell; Editing by Peter Henderson and Aurora Ellis)

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *